Patients with type 2 diabetes (T2DM) who require injectable therapy have been conventionally treated with insulin. A glucagon-like peptide 1 receptor agonist was recently recommended as first-line injectable treatment, but few studies have investigated the effects of switching from insulin to dulaglutide. This study investigated the clinical efficacy and parameters affecting responses to dulaglutide as an alternative to insulin in patients with T2DM in a real-world clinical setting.

中文翻译：

---

2 型糖尿病患者从胰岛素转为度拉鲁肽治疗：真实世界数据研究

需要注射治疗的 2 型糖尿病 (T2DM) 患者通常接受胰岛素治疗。胰高血糖素样肽 1 受体激动剂最近被推荐作为一线注射治疗，但很少有研究调查从胰岛素转换为度拉鲁肽的影响。本研究调查了在真实世界的临床环境中，T2DM 患者对度拉鲁肽作为胰岛素替代品的临床疗效和影响反应的参数。